Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma
详细信息 查看全文
- 作者：Maria Cristina Rapanotti (1)
Tara Mayte Suarez Viguria (1)
Gaetana Costanza (3)
Ilaria Ricozzi (2)
Andrea Pierantozzi (1)
Alessandro Di Stefani (3)
Elena Campione (2)
Sergio Bernardini (1)
Sergio Chimenti (2)
Augusto Orlandi (3)
Luca Bianchi (2) - 关键词：Melanoma ; MCAM/MUC18 expression ; Disease biomarker ; AJCC stages
- 刊名：Archives of Dermatological Research
- 出版年：2014
- 出版时间：August 2014
- 年：2014
- 卷：306
- 期：6
- 页码：527-537
- 全文大小：729 KB
- 参考文献：1. Alais S, Allioli N, Pujades C, Duband JL, Vainio O, Imhof BA, Dunon D (2001) HEMCAM/CD146 downregulates cell surface expression of beta1 integrins. J Cell Sci 114:1847-859
2. Aubin F, Chtourou M, Teyssier JR, Laubriet A, Mougin CH, Blanc D, Humbert P (2000) The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res 10:113-18 CrossRef
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-648
4. Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, Bar-Eli M (2014) Why is melanoma so metastatic? Pigment Cell melanoma Res 27:19-6 CrossRef
5. Campagnolo L, Costanza G, Francesconi A, Arcuri G, Moscatelli I, Orlandi A (2014) Sortilin expression is essential for pro-nerve growth factor-induced apoptosis of rat vascular smooth muscle cells. PLoS ONE 9:e84969 CrossRef
6. Capoluongo E, Paolillo C, Vendittelli F (2014) Is qRT-PCR MCAM transcript assay really suitable for prognostic and predictive management of melanoma patients? Br J Dermatol. doi:10.1111/bjd.12818
7. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 162:156-59 CrossRef
8. Clark WH Jr, Elder DE, Van Horn M (1986) The biologic forms of malignant melanoma. Hum Pathol 17:443-50 CrossRef
9. Curry BJ, Myers K, Hersey P (1998) Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 16:1760-769
10. Curry BJ, Myers K, Hersey P (1999) MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 17:2562-571
11. Dye DE, Medic S, Ziman M, Coombe DR (2013) Melanoma biomolecules: independently identified but functionally intertwined. Front Oncol 3:252 CrossRef
12. Ferlosio A, Arcuri G, Doldo E, Scioli MG, De Falco S, Spagnoli LG, Orlandi A (2012) Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis 224:51-7 CrossRef
13. Fritzsche FR, Wassermann K, Rabien A, Schicktanz H, Dankof A, Loening SA, Dietel M, Jung K, Kristiansen G (2008) CD146 protein in prostate cancer: revisited with two different antibodies. Pathology 40:457-64 CrossRef
14. Ghossein RA, Rosai J (1996) Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 78:10-6 CrossRef
15. Ghossein RA, Bhattacharya S, Rosai J (1999) Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 5:1950-960
16. Gkalpakiotis S, Arenberger P, Kremen J, Arenbergerova M (2010) Quantitative detection of melanoma-associated antigens by multimarker real-time RT-PCR for molecular staging: results of a 5?years study. Exp Dermatol 19:994-99 CrossRef
17. Guo J, Wen DR, Huang RR, Paul E, Wunsch P, Itakura E, Cochran AJ (2003) Detection of multiple melanoma-associated markers in melanoma cell lines by RT in situ PCR. Exp Mol Pathol 74:140-47 CrossRef
18. Haass NK, Smalley KS, Li L, Herlyn M (2005) Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 18:150-59 CrossRef
19. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH (1999) The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res 9:465-73 CrossRef
20. Holzmann B, Brocker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmuller G, Johnson JP (1987) Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 39:466-71 CrossRef
21. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL (1995) Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13:2109-116
22. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, Morton DL (2000) Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 60:2253-257
23. Hu XC, Loo WT, Chow LW (2003) Surgery-related shedding of breast cancer cells as determined by RT-PCR assay. J Surg Oncol 82:228-32 discussion 233 CrossRef
24. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58-8 CrossRef
25. Larson AR, Konat E, Alani RM (2009) Melanoma biomarkers: current status and vision for the future. Nat Clin Pract Oncol 6:105-17 CrossRef
26. Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G, Johnson JP (1987) Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47:841-45
27. Lehmann JM, Riethmuller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Pro Natl Acad Sci USA 86:9891-895 CrossRef
28. Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, Kelly JW (2006) Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 142:1551-558
29. Luca M, Hunt B, Bucana CD, Johnson JP, Fidler IJ, Bar-Eli M (1993) Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 3:35-1 CrossRef
30. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153:865-73 CrossRef
31. Max N, Keilholz U (2001) Minimal residual disease in melanoma. Semin Surg Oncol 20:319-28 CrossRef
32. McCulloch P, Choy A, Martin L (1995) Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334-335 CrossRef
33. McGary EC, Lev DC, Bar-Eli M (2002) Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 1:459-65 CrossRef
34. Mellado B, Gutierrez L, Castel T, Colomer D, Fontanillas M, Castro J, Estape J (1999) Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 5:1843-848
35. Melnikova VO, Bar-Eli M (2006) Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 19:395-05 CrossRef
36. Mikhaylova IN, Kovalevsky DA, Morozova LF, Golubeva VA, Cheremushkin EA, Lukashina MI, Voronina ES, Burova OS, Utyashev IA, Kiselev SL, Demidov LV, Beabealashvilli R, Baryshnikov AY (2008) Cancer/testis genes expression in human melanoma cell lines. Melanoma Res 18:303-13 CrossRef
37. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M (2002) Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62:5106-114
38. Mobley AK, Braeuer RR, Kamiya T, Shoshan E, Bar-Eli M (2012) Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev 31:621-32 CrossRef
39. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR (2006) The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 12:4605-613 CrossRef
40. Orlandi A, Ferlosio A, Ciucci A, Francesconi A, Lifschitz-Mercer B, Gabbiani G, Spagnoli LG, Czernobilsky B (2006) Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. Mod Pathol 19:797-03
41. Orlandi A, Costantini S, Campione E, Ferlosio A, Amantea A, Bianchi L, Chimenti S, Spagnoli LG (2009) Relation between animal-type melanoma and reduced nuclear expression of glutathione S-transferase pi. Arch Dermatol 145:55-2 CrossRef
42. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD (2005) Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 115:367-75 CrossRef
43. Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G (1999) Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 17:304-11
44. Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, Napolitano M, Caraco C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C, Satriano RA, Castello G (2003) Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 21:767-73 CrossRef
45. Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253:180-04 CrossRef
46. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R (2008) Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. JPRAS 61:265-71
47. Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, Clack G, Malone M, Coumans FA, Terstappen LW (2011) Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 38:755-60 CrossRef
48. Rapanotti M, Ricozzi I, Campione E, Orlandi A, Bianchi L (2013) Blood MUC-18/MCAM expression in melanoma patients: a suitable marker of poor outcome. Br J Dermatol 169:221-22. doi:10.1111/bjd.12295 CrossRef
49. Rapanotti MC, Bianchi L, Ricozzi I, Campione E, Pierantozzi A, Orlandi A, Chimenti S, Federici G, Bernardini S (2009) Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients. Br J Dermatol 160:338-44 CrossRef
50. Reid AL, Millward M, Pearce R, Lee M, Frank MH, Ireland A, Monshizadeh L, Rai T, Heenan P, Medic S, Kumarasinghe P, Ziman M (2013) Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol 168:85-2 CrossRef
51. Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC (2003) Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 9:1497-502
52. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M (2001) Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 20:4676-684 CrossRef
53. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C (1999) Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 141:30-6 CrossRef
54. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, Thiel E, Foerster MH, Keilholz U (2007) Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 13:1171-178 CrossRef
55. Shih IM (1999) The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 189:4-1 CrossRef
56. Shih LM, Hsu MY, Palazzo JP, Herlyn M (1997) The cell–cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol 151:745-51
57. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-229 CrossRef
58. Stalin J, Harhouri K, Hubert L, Subrini C, Lafitte D, Lissitzky JC, Elganfoud N, Robert S, Foucault-Bertaud A, Kaspi E, Sabatier F, Aurrand-Lions M, Bardin N, Holmgren L, Dignat-George F, Blot-Chabaud M (2013) Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin. J Biol Chem 288:8991-000 CrossRef
59. Takeuchi H, Kuo C, Morton DL, Wang HJ, Hoon DS (2003) Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res 63:441-48
60. Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330:150-62 CrossRef
61. Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang HJ, Gerami M, Hoon DS (2003) Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 21:2558-563 CrossRef
62. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M (1997) Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57:2295-303
63. Zhang Y, Zheng C, Zhang J, Yang D, Feng J, Lu D, Yan X (2008) Generation and characterization of a panel of monoclonal antibodies against distinct epitopes of human CD146. Hybridoma 27:345-52 CrossRef - 作者单位：Maria Cristina Rapanotti (1)
Tara Mayte Suarez Viguria (1)
Gaetana Costanza (3)
Ilaria Ricozzi (2)
Andrea Pierantozzi (1)
Alessandro Di Stefani (3)
Elena Campione (2)
Sergio Bernardini (1)
Sergio Chimenti (2)
Augusto Orlandi (3)
Luca Bianchi (2)
1. Department of Laboratory Medicine, University of “Tor Vergata-Rome, Rome, Italy
3. Department of Anatomic Pathology, University of “Tor Vergata-Rome, Rome, Italy
2. Department of Dermatology, University of “Tor Vergata-Rome, Policlinico di Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy - ISSN：1432-069X
文摘
MCAM/MUC18 is a cell adhesion molecule associated with higher incidence of relapse in melanoma. The purpose of our study was to evaluate its role as a promising disease biomarker of progression through sequential molecular MCAM/MUC18 RT-PCR assay on serial blood samples collected during the clinical follow-up of 175 melanoma patients in different American Joint Committee on Cancer (AJCC) stages. MCAM/MUC18 molecular detection, found at least once in 22 out of the 175 patients, was significantly associated with poor prognosis and death (p?AJCC stages. Positive expression, either if primarily present or later acquired, was associated with melanoma progression, whereas patients primarily negative or with subsequent loss gained clinical remission or stable disease, even if in advanced stages (p?AJCC advanced stages always MCAM/MUC18 negative are in complete remission or with a stable disease (p?AJCC stages and clinical outcome were statistically evaluated using Student’s t test, ANOVA, Spearman’s rank correlation test, Pearson χ 2-test and McNemar’s test. In our investigation, MCAM/MUC18 expression behaves as a “molecular warning of progression-even in early AJCC patients otherwise in disease-free conditions. Achievement of this molecule predicted the emergence of a clinically apparent status, whereas absence or persistent loss was related to a stable disease or to a disease-free status. If confirmed in larger case series, MCAM/MUC18 molecular expression could predict good or poor clinical outcome, possibly becoming a promising prognostic factor.